Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs)
$107.56
pos +0.05
+0.05%
Today's Range: 106.78 - 108.24 | GILD Avg Daily Volume: 12,017,000
Last Update: 08/29/14 - 4:00 PM EDT
Volume: 11,324,215
YTD Performance: 43.22%
Open: $107.90
Previous Close: $107.51
52 Week Range: $58.81 - $108.77
Oustanding Shares: 1,511,670,456
Market Cap: 162,519,690,725
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 11 15 15
Moderate Buy 1 1 1 2
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.33 1.36 1.28 1.32
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 24.21
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
24.21 24.20 28.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
31.04% 76.53% 440.64%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.50 0.41 0.12
Net Income 18.80 0.06 0.02
EPS 10.80 0.18 0.06
Earnings for GILD:
EBITDA 4.87B
Revenue 11.20B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.64 $2.22 $7.26 $9.07
Number of Analysts 3 3 3 3
High Estimate $1.85 $2.81 $8.34 $10.13
Low Estimate $1.35 $1.52 $5.51 $7.31
Prior Year $0.50 $0.52 $1.92 $7.26
Growth Rate (Year over Year) 227.33% 326.28% 278.30% 24.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Aug 29, 2014 | 9:34 AM EDT

Here's how you can get on the bandwagon.

By

Bret Jensen

 | Aug 28, 2014 | 10:30 AM EDT

I'd advise picking up these two stocks before year-end.

By

Gary Dvorchak

 | Aug 21, 2014 | 2:08 PM EDT
For accountability's sake, here is an update on my on my current five best ideas.
By

Bret Jensen

 | Aug 18, 2014 | 12:30 PM EDT

There has been huge progress in treating this lethal disease.

bullishGilead rated new Outperform at FBR

Aug 15, 2014 | 7:22 AM EDT

GILD was initiated with an Outperform rating, FBR Capital Markets said. $125 price target. Hepatitis C market has net been fully appreciated by the market and can drive growth over the next 15 years.

 

 

By

Jim Cramer

 | Aug 13, 2014 | 1:18 PM EDT

Biotech stocks are thriving in a slower-growth, low-inflation world.

By

Timothy Collins

 | Aug 8, 2014 | 1:09 PM EDT
The quick and dirty on Gilead Sciences.
By

Bret Jensen

 | Aug 5, 2014 | 8:30 AM EDT

Pace yourself for a marathon, don't try to beat others in a sprint.

By

Jim Cramer

 | Aug 4, 2014 | 11:45 AM EDT

These quality names look appealing on the basis of 30-week moving average.

By

Bret Jensen

 | Aug 1, 2014 | 2:38 PM EDT
We'll see.

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.